Quest Diagnostics' Accelerating Diversification: Partnerships and Consumer Health Drive a Sharp Re-rating
Q2 2026: Organic revenue up 10%, volume up 13%, and a 28% stock rally as Co-Lab and advanced diagnostics reshape the growth profile.
DGX · Earnings Call · 2026-07-23
A Quarter of Acceleration
Quest Diagnostics (DGX) reported a second quarter that clearly exceeded expectations, and the market responded with a 28% rally over the past 90 days. The company grew consolidated revenues by over 10% organically, with total volumes up 13.1%—a figure that stands out even when stripping out the contribution from the Corewell Health and Fresenius Medical Care collaborations, which together added 9% to volume growth.
Total volume measured by the number of requisitions increased 13.1% versus the second quarter of 2025 with organic volume up 13%.
“we grew revenues by over 10%, driven by broad clinical demand from physicians, hospitals and consumers and increased volume from our collaborations with Corewell Health and Fresenius Medical Care.” — James Davis, Chairman, Chief Executive Officer and President · 2026-07-23 The momentum is broad-based, spanning the physician channel, hospital reference testing, and consumer-initiated testing.
The key driver this quarter is the successful scaling of two transformative partnerships. Corewell Health's Co-Lab volume is ramping as anticipated, and Fresenius Medical Care's dialysis testing is contributing around $100 million in annualized revenue at improving margins. Jim Davis highlighted the importance of these deals: “The Fresenius book of business is a significant revenue increase year-over-year as well, close to $100 million. And the margin profile of that business continues to improve from Q1 to Q2 to Q3 and into Q4.” — James Davis, Chairman, Chief Executive Officer and President · 2026-07-23 These relationships are not just revenue boosts; they bring deeper capabilities in kidney care and hospital lab management, positioning Quest as an indispensable partner.
The Consumer and Advanced Diagnostics Engine
Beyond the partnerships, Quest is thriving on the convergence of Consumer Health, advanced diagnostics, and AI. The consumer health channel, including QuestDirect and collaborations with wellness platforms, continues to grow at a 20-30% pace. Meanwhile, the Advanced Diagnostic portfolio is a clear differentiator. In particular, the Haystack MRD test achieved New York State approval, a rigorous endorsement that unlocks the important New York market. “New York State approved the test, placing it among an elite group of solid tumor ctDNA MRD test to fulfill the state's rigorous quality criteria.” — James Davis, Chairman, Chief Executive Officer and President · 2026-07-23 The company also inked a partnership with Flatiron Health to extend oncology test ordering to thousands of clinicians.
These trends are feeding directly into the test per req volume, which is now north of 4.5 tests per requisition, up from 3.5-4.0 pre-COVID. This mix shift, along with flat unit pricing, drove revenue per requisition up 2.9% ex-mix. As Sam Samad noted, “revenue per requisition was down 2.8% versus the prior year due to the Corewell and Fresenius business mix. Adjusting for that business mix, revenue per requisition was up by 2.9% versus prior year, driven primarily by an increase in the number of tests per requisition.” — Sam Samad, Chief Financial Officer · 2026-07-23 The consumer and wellness ecosystem is also a margin tailwind, as these are cash-pay, low-denial businesses.
Financial Firepower and a Reduced Risk Profile
The balance sheet supports continued investment. Total Revenue has grown steadily over the past decade, and operating margins are expanding despite the dilutive ramp of Corewell and Fresenius. Management raised full-year 2026 guidance again, now expecting revenue of $11.95-12.05 billion and adjusted EPS of $11.05-11.25. The company also expects operating margins to be up year-over-year, a testament to its Invigorate productivity program. This is a re-rating story: the stock has responded, and with compelling growth drivers and improving margins, the market is rewarding a clear strategic pivot.
The Market's Verdict
The 90-day price tape shows a +28% move, the strongest in over a decade, and the stock is now near its all-time highs. The combination of durable organic growth, a validated M&A/integration playbook, and exposure to the secular consumer health and AI-in-healthcare trends makes Quest a rare large-cap growth story in diagnostics. The prior quarter already hinted at this acceleration, with organic volume up 10.8% and Alzheimer's testing more than doubling year-over-year. “organic volume growth was 10.8% in the quarter” — Sam Samad, Chief Financial Officer · 2026-04-21 and “our Alzheimer's book of testing more than doubled year-over-year.” — James Davis, Chairman, Chief Executive Officer and President · 2026-04-21 The Q2 results confirm that the secular tailwinds are not a one-quarter phenomenon.
Quest Diagnostics is executing on multiple fronts, and the market is paying attention. With consumer health, advanced diagnostics, and strategic collaborations all firing, the company's accelerated growth and margin expansion are likely to persist. The risk to the story remains policy-driven, particularly PAMA, but management's active advocacy for the RESULTS Act provides a potential safety net. For now, the tape says it all: Quest Diagnostics is a growth story again.